Drano, Interesting concept to go it alone. It may boil down to what is the quickest path to market and which alternative yields the most profits to IPIX. The following example are numbers I completely made up for sake of comparison analysis that IPIX has probably looked at. For example Option A of IPIX taking B-OM alone to market may produce $200M/yr in revenue after minimal marketing costs by IPIX. Option B is securing a partnership with a large pharma that could generate $1B/yr in sales of B-OM due to their large sales, marketing and distribution presence in the market along with big buck advertising budgets. A 20% IPIX royalty in this example would equal the same $200M/yr in profit. My guess is that both options are legit.